Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data

The Journal of Steroid Biochemistry and Molecular Biology
Harald Seeger, Alfred O Mueck

Abstract

Evidence is increasing suggesting that adding progestins to estrogen replacement therapy may be more harmful then beneficial, however it is debatable whether all progestins act equally on breast epithelial cells. Experimental data with the comparison of various progestins in the same in vitro model present a rather high evidence that there may be differences between the various progestins regarding breast cancer risk. Especially of concern may be to differentiate between primary and secondary risk i.e. between benign and malignant breast epithelial cells. The epidemiological studies and especially the Women's Health Initiative (WHI) trial, so far the only prospective placebo-controlled interventional study, demonstrate an increased risk under combined estrogen/progestin therapy, but they have the limitations that they up to now cannot discriminate between the various progestins mostly due to too small or not comparable patient numbers in the subgroups with the various progestins. However, there is evidence that the natural progesterone, possibly also the transdermal usage of synthetic progestins, may avoid an increased risk, but this must be proven in further clinical trials.

References

Jun 1, 1992·The Journal of Steroid Biochemistry and Molecular Biology·B van der BurgS W de Laat
Apr 29, 1993·The New England Journal of Medicine·W C Black, H G Welch
Sep 25, 1997·International Journal of Cancer. Journal International Du Cancer·I PerssonL Holmberg
Dec 2, 1998·International Journal of Cancer. Journal International Du Cancer·A F GazdarJ W Shay
Apr 21, 1999·International Journal of Cancer. Journal International Du Cancer·C MagnussonI Persson
Dec 7, 2000·Journal of the National Cancer Institute·D F ArcherL E Nachtigall
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Nov 19, 2002·Annals of Internal Medicine·Wendy Y ChenFrank E Speizer
Dec 7, 2002·Obstetrics and Gynecology·Linda K WeissRobert Spirtas
Jun 26, 2003·JAMA : the Journal of the American Medical Association·Rowan T ChlebowskiUNKNOWN WHI Investigators
Aug 21, 2003·Lancet·Valerie Beral, UNKNOWN Million Women Study Collaborators
Mar 5, 2004·International Journal of Cancer. Journal International Du Cancer·Claudia StahlbergBent Ottesen
Apr 30, 2005·The Journal of Steroid Biochemistry and Molecular Biology·J P WiebeG Zhang
Sep 20, 2005·International Journal of Cancer. Journal International Du Cancer·Sulggi LeeMalcolm Pike
Jan 5, 2006·Climacteric : the Journal of the International Menopause Society·Richard Farmer
Feb 8, 2006·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Elizabeth A KrämerAlfred O Mueck
Dec 18, 2007·BJOG : an International Journal of Obstetrics and Gynaecology·L OpatrnyS Suissa

❮ Previous
Next ❯

Citations

May 9, 2009·Breast Cancer Research and Treatment·UNKNOWN MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Aug 13, 2009·Breast Cancer Research and Treatment·UNKNOWN MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Aug 13, 2009·Breast Cancer Research and Treatment·UNKNOWN MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Oct 22, 2008·Human Reproduction Update·B GellersenJ J Brosens
Mar 11, 2010·Menopause : the Journal of the North American Menopause Society·Kerstin L EdlefsenGarnet Anderson
Jun 23, 2011·Molecular Medicine·Fahim AtifDonald G Stein
Apr 13, 2012·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Xiangyan RuanHans Neubauer
Nov 3, 2012·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Helen SchneckHans Neubauer
Jul 21, 2010·Climacteric : the Journal of the International Menopause Society·G NoéH B Croxatto
Feb 18, 2012·Climacteric : the Journal of the International Menopause Society·X RuanA O Mueck
Nov 1, 2011·Hormone Molecular Biology and Clinical Investigation·Joaquín Cortés-PrietoHugh Ahern
Oct 21, 2016·Expert Opinion on Drug Safety·Santiago Palacios, Andrea Mejía
Sep 10, 2009·International Journal of Cancer. Journal International Du Cancer·UNKNOWN MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Dec 1, 2010·Hormone Molecular Biology and Clinical Investigation·Alfred O MueckSamuel Shapiro
Nov 30, 2012·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Néstor ToledoSergio F Vizcaíno
Mar 14, 2019·Climacteric : the Journal of the International Menopause Society·X LiA O Mueck
Mar 27, 2020·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Guiju CaiAlfred O Mueck
Mar 1, 2011·Hormone Molecular Biology and Clinical Investigation·Alfred O Mueck, Xiangyan Ruan
Apr 26, 2013·Menopause : the Journal of the North American Menopause Society·Hans NeubauerAlfred O Mueck

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2021 Meta ULC. All rights reserved